Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902219-25-000271
Filing Date
2025-08-12
Accepted
2025-08-12 10:34:26
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9494
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 3749
  Complete submission text file 0000902219-25-000271.txt   15317
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 200 - 3650 GILMORE WAY BURNABY British Columbia, Canada
Business Address 200 - 3650 GILMORE WAY BURNABY British Columbia, Canada (604) 484-3300
Xenon Pharmaceuticals Inc. (Subject) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88403 | Film No.: 251204910
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)